21 May 2013
Keywords: novartis, once-yearly, aclasta, cuts, spine, fracture, risk
Article | 14 May 2007
Switzerland-based drug major Novartis says that its drug Aclasta (zoledronic acid; sold as Reclast in the USA) cuts the risk ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 May 2007
20 May 2013
© 2013 thepharmaletter.com